Clinical Trials Logo

Filter by:
NCT ID: NCT04453982 Active, not recruiting - Sars-CoV2 Clinical Trials

Is COVID-19 Transmitted Through Human Milk? Implications for Breastfeeding and Human Milk Banking-Study 1b

Start date: June 21, 2020
Phase:
Study type: Observational

The Canadian Paediatric Society recommends breastfeeding during COVID-19 infection. Human milk is the best form of infant nutrition providing significant protection against many illnesses for term and preterm infants. When mothers of hospitalized infants are unable to supply their milk, the recommended supplement is human donor milk. The impact of a pandemic on human milk banking is unknown. This study seeks to address this public health issue. Donor milk will be collected from the Rogers Hixon Ontario Human Milk Bank at Sinai Health System in Toronto. Samples will be analyzed for the COVID-19 virus specific nucleic acid and antibody in real-time and results will be immediately disseminated to relevant organizations to inform local, national and international guidelines surrounding donor milk banking to protect the health of infants.

NCT ID: NCT04453969 Active, not recruiting - SARS-CoV2 Clinical Trials

Is COVID-19 Transmitted Through Human Milk? Implications for Breastfeeding and Human Milk Banking-Study 1a

Start date: May 24, 2020
Phase:
Study type: Observational

The Canadian Paediatric Society recommends breastfeeding during COVID-19 infection. Human milk is the best form of infant nutrition providing significant protection against many illnesses for term and preterm infants. The impact of a pandemic on breastfeeding is unknown. This study seeks to address this public health issue. Breastmilk will be collected from mothers positive for COVID-19. Samples will be analyzed for the COVID-19 virus specific nucleic acid and antibody in real-time and results will be immediately disseminated to relevant organizations to inform local, national and international guidelines surrounding breastfeeding to protect the health of infants.

NCT ID: NCT04453774 Active, not recruiting - Coronavirus Clinical Trials

At Home Monitoring for Patients With Covid19

Start date: November 1, 2020
Phase: N/A
Study type: Interventional

The vast majority of individuals with Covid19 have mild illness that can be managed in the outpatient setting. A small but significant number of these people will deteriorate and require hospitalization. Symptoms are a poor - and possibly late - indicator for deterioration. While people who have died, and/or been cared for in the ICU or hospital have been well characterized, there remains a dearth of information about the clinical course of people in the outpatient setting. Most notably, it is not known when to escalate to hospital care. The consequence of non-escalation when needed is significant patient morbidity and mortality, of escalation when not needed is unnecessarily overwhelmed hospitals. Technologies for clinical management and early diagnostics for severe Covid19 infection will address this challenge. The research goal of this study is to use real-time remote patient monitoring to detect which patients with Covid19 are at risk of deterioration to bring to hospital, while at the same ensuring the worried will receive reassurance so they stay at home. The clinical goal is to help clinicians provide excellent care using ubiquitous mobile phones.

NCT ID: NCT04452461 Recruiting - Clinical trials for Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma Neoadjuvant Chemotherapy Before Surgery

PANCREAS
Start date: March 1, 2021
Phase: Phase 2
Study type: Interventional

This is a single-arm, single-center feasibility trial of patients with borderline resectable pancreatic adenocarcinoma receiving chemotherapy with mFOLFIRINOX or gemcitabine / nab-paclitaxel followed by pancreatectomy.

NCT ID: NCT04451668 Completed - Sleep Disturbance Clinical Trials

An Open Label Study of FT218 in Subjects With Narcolepsy

RESTORE
Start date: June 12, 2020
Phase: Phase 3
Study type: Interventional

An Open Label Study to Evaluate Long-Term Safety and Tolerability of a Once Nightly Formulation of Sodium Oxybate for Extended-Release Oral Suspension (FT218) and the ability to switch from twice-nightly immediate release sodium oxybate to once-nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Subjects with Narcolepsy

NCT ID: NCT04451590 Recruiting - Virtual Reality Clinical Trials

Virtual Reality: a Teaching-learning Strategy for Cognitive Mastery in Airway Trauma Management

AW&VR
Start date: August 1, 2021
Phase: N/A
Study type: Interventional

Airway injury in patients is a high risk and complex medical crisis. Unfortunately, training for airway management in injured patients is challenging. The most effective way of practicing airway management is using mannequins. However, mannequin training is expensive and only occasionally available to medical trainees. The purpose of this study is to determine if Virtual Reality (VR) can be used to educate medical students on airway injury management. VR training will involve managing the care of a patient with an airway injury in an immersive, interactive VR hospital trauma bay. The investigators will compare the knowledge gained from VR training vs. mannequin training. The investigators will also investigate whether VR training teaches students faster than mannequin training. In addition, the investigators will identify factors which might affect learning from VR. Medical students who choose to participate will be randomized (i.e. participant will have a 50% chance to be placed in either group) to be trained with VR or a mannequin. Participants then will be trained on airway injury management using their assigned training approach. One week later, all participants will be assessed on their airway injury management skills using a mannequin. Before and after their sessions, participants will also be asked to complete a questionnaire on their clinical decision-making. Participants who received VR training will also complete a questionnaire about their experience with the VR training. This study will help develop a new approach to airway management training which is cheaper and more easily available to medical trainees than mannequin training. This educational tool could lead to better treatment of airway trauma in future patients.

NCT ID: NCT04451291 Completed - COVID-19 Clinical Trials

Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure

Start date: September 25, 2020
Phase: N/A
Study type: Interventional

This is a research study to see how safe and effective decidual stromal cells are in treating patients with respiratory failure (breathing problem where not enough oxygen is passed from the lungs into the blood) caused by COVID-19.

NCT ID: NCT04451044 Enrolling by invitation - Clinical trials for Coronary Artery Disease

Distal Evaluation of Functional Performance With Intravascular Sensors to Assess the Narrowing Effect: Guided Physiologic Stenting

DEFINE GPS
Start date: June 17, 2021
Phase: N/A
Study type: Interventional

Multi-center, prospective, randomized controlled study comparing PCI guided by angiography versus iFR Co-Registration using commercially available Philips pressure guidewires and the SyncVision co-registration system, employing an adaptive design study for interim sample size re-estimation.

NCT ID: NCT04450563 Completed - Type 1 Diabetes Clinical Trials

Low Dose Empagliflozin in Adults With Type 1 Diabetes on Closed Loop Insulin System

CL-LoDE
Start date: November 2, 2020
Phase: Phase 1
Study type: Interventional

A closed-loop insulin system, also referred to as the "artificial pancreas" (AP), is made up of an insulin pump, a continuous glucose monitor, and an application communicating between the two to adjust insulin administration based on glucose control. This is meant for the treatment of type 1 diabetes. The McGill Artificial Pancreas (MAP) has been used previously in type 1 diabetes with significant benefits. Though prior studies have shown significant benefit with this system, some challenges still exist. Empagliflozin is used in type 2 diabetes; it allows for glucose to be removed through the urine. Though its use is not approved in type 1 diabetes in North America, it (along with similar drugs) has been used in studies as adjunctive therapy with insulin with benefits on blood sugar control. The purpose of our study is to see if a small dose of empagliflozin (2.5 mg and 5 mg) is enough to help those who cannot achieve adequate glucose control on a closed-loop insulin system. The primary hypotheses of the study are the following: 1. The use of empagliflozin 2.5 mg daily will increase time in range compared to placebo for those on the closed-loop system. 2. The use of empagliflozin 5 mg daily will increase time in range compared to placebo for those on the closed-loop system.

NCT ID: NCT04450342 Terminated - Clinical trials for Rotator Cuff Injuries

REGENETEN™ Bioinductive Implant System in Full-thickness Tears

REGENETEN
Start date: December 7, 2020
Phase: N/A
Study type: Interventional

The study is designed to assess the safety and efficacy of Arthroscopic rotator cuff repair (ARCR) augmented with REGENETEN in subjects requiring full-thickness rotator cuff tear repair or revision repair versus Arthroscopic rotator cuff repair alone.